Navigation Links
Gene Warfare and Lobular Cancer

Every one in ten or fifteen cases of breast cancer can be attributed to Classic Lobular Carcinomas (CLC).//

Breast tissue is made up of ducts or tubes and lobules( milk producing glands). Invasive(spreading) lobular cancer can occur in women of the age group 45 to 55. As the symptoms of this cancer show up as thickened portions of breast tissue rather than definite hardened lumps, they may not be noticed immediately causing the tumours to spread. Diagnosis involves tests like mammogram, ultrasound scan, fine needle aspiration and needle core biopsy.

Though it may not be considered deadlier than other cancers of the breast, there is a chance of CLC ocuring in both breasts, or spreading from one breast to the other. Very little is known about the supposed methods of targeting the tumors found in invasive lobular cancer.

A study (published in Clinical Cancer Research) was done by subjecting 13 cases of CLC to molecular and tissue analysis. It was seen that the presence of a gene FGFR1 contributed to the survival of certain cancerous cells in these tumors. Hence it was suggested that inhibitors or suppressants of this gene could be used in formulating drugs intended for the therapy of this type of carcinoma.
'"/>




Page: 1

Related medicine news :

1. Excavations Reveal Clues Of Early Warfare
2. Atypical Lobular Hyperplasia increases risk of breast cancer
3. Fibroids unlikely to Turn Cancerous
4. Virus Level could Predict Cervical Cancer Risk
5. Cancer Doctors Okays Controversial Prostate Therapy
6. Potential New Cancer Gene Identified
7. Consensus on "Combination Therapy" for Breast Cancer
8. Cancers of Colon & Rectum linked to Cigarette Smoking
9. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
10. The Cancer Rumour mill working over time
11. Cancer drugs in development nearly doubled since 1995
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... Washington, DC (PRWEB) , ... April 28, 2017 ... ... Unplanned Pregnancy (The National Campaign) announces its support for the Access to ... by Sen. Jeanne Shaheen (D-NH) and Rep. Jackie Speier (D-CA), will help to ...
(Date:4/28/2017)... ... 2017 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced ... its outlook as “stable.” At the same time, the ratings agency cautioned that the ... dip below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed ...
(Date:4/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce its ... has been in place since the RBMA was founded in 1968 with all board ... Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer for Clinical ...
(Date:4/28/2017)... Ca (PRWEB) , ... April 28, 2017 , ... ... cardiac or hERG liability could substantially improve drug safety and minimize the cost ... provided for validating ion channel inhibition using cell lines and for cardiac toxicity ...
(Date:4/28/2017)... UTAH (PRWEB) , ... April 28, 2017 , ... ... Account Manager for the North East region. Côté has 20+ years of experience ... Prior to Phytomer, Côté worked with an array of high-end cosmetic brands, retail ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Manufacturing Services Market Analysis By Service (Manufacturing, Research), By Country, ... - 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing ... 2025 Low drug registration cost in Latin American ...
(Date:4/19/2017)... 19, 2017 The Mobile X-Ray product segment is ... CAGR during the forecast period Mobile X-Ray segment ... digital mobile X-Ray devices market, which is estimated to be ... at a CAGR of 7% over the forecast period. Mobile ... more than US$ 100 Mn in 2017 over 2016. The ...
(Date:4/19/2017)... YORK , April 19, 2017 ... This report on the prostate cancer therapeutics ... the global market. Increasing prevalence of prostate cancer, ... innovation in the development of new drugs & ... prostate cancer drug due to lesser side effects ...
Breaking Medicine Technology: